{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:06:27Z","timestamp":1792757187541,"version":"4.5.0"},"reference-count":85,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2021,1,5]]},"DOI":"10.1001\/jama.2020.18936","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T07:41:25Z","timestamp":1610091685000},"page":"69","source":"Crossref","is-referenced-by-count":342,"title":["Management of Crohn Disease"],"prefix":"10.1001","volume":"325","author":[{"given":"Kelly","family":"Cushing","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter D. R.","family":"Higgins","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10114","key":"jrv200013r1","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.","volume":"390","author":"Ng","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"jrv200013r2","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1053\/j.gastro.2015.08.001","article-title":"Genetics of inflammatory bowel diseases.","volume":"149","author":"McGovern","year":"2015","journal-title":"Gastroenterology"},{"issue":"7422","key":"jrv200013r3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nature11582","article-title":"Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.","volume":"491","author":"Jostins","year":"2012","journal-title":"Nature"},{"issue":"9","key":"jrv200013r4","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/ng.3359","article-title":"Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations.","volume":"47","author":"Liu","year":"2015","journal-title":"Nat Genet"},{"issue":"3","key":"jrv200013r5","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.gtc.2017.05.004","article-title":"The microbiome in Crohn\u2019s disease: role in pathogenesis and role of microbiome replacement therapies.","volume":"46","author":"Khanna","year":"2017","journal-title":"Gastroenterol Clin North Am"},{"issue":"11","key":"jrv200013r6","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.4065\/81.11.1462","article-title":"Smoking and inflammatory bowel disease: a meta-analysis.","volume":"81","author":"Mahid","year":"2006","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"jrv200013r7","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/apt.13511","article-title":"Systematic review with meta-analysis: the adverse effects of tobacco smoking on the natural history of Crohn\u2019s disease.","volume":"43","author":"To","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"jrv200013r8","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1111\/apt.2013.38.issue-7","article-title":"Smoking does influence disease behaviour and impacts the need for therapy in Crohn\u2019s disease in the biologic era.","volume":"38","author":"Nunes","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"jrv200013r9","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1111\/apt.2018.47.issue-10","article-title":"Risk factors for diagnostic delay in Crohn\u2019s disease and their impact on long-term complications: how do they differ in a tuberculosis endemic region?","volume":"47","author":"Banerjee","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"jrv200013r10","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.dld.2015.03.004","article-title":"Diagnostic delay in Crohn's disease is associated with increased rate of abdominal surgery: a retrospective study in Chinese patients.","volume":"47","author":"Li","year":"2015","journal-title":"Dig Liver Dis"},{"issue":"10","key":"jrv200013r11","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1097\/MIB.0000000000001257","article-title":"Impact of diagnostic delay and associated factors on clinical outcomes in a U.S. inflammatory bowel disease cohort.","volume":"23","author":"Nguyen","year":"2017","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"jrv200013r12","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1093\/ecco-jcc\/jjx138","article-title":"Changes in disease behaviour and location in patients with Crohn\u2019s disease after seven years of follow-up: a Danish population-based inception cohort.","volume":"12","author":"Lo","year":"2018","journal-title":"J Crohns Colitis"},{"issue":"6","key":"jrv200013r13","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/ajg.2015.120","article-title":"C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis.","volume":"110","author":"Mosli","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"jrv200013r14","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1053\/j.gastro.2010.06.070","article-title":"Risk factors associated with progression to intestinal complications of Crohn\u2019s disease in a population-based cohort.","volume":"139","author":"Thia","year":"2010","journal-title":"Gastroenterology"},{"key":"jrv200013r15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1159\/000342608","article-title":"Clinical risk factors for complicated disease: how reliable are they?","volume":"30","author":"Zallot","year":"2012","journal-title":"Dig Dis"},{"issue":"5","key":"jrv200013r16","first-page":"631","article-title":"The prevalence and incidence of axial and peripheral spondyloarthritis in inflammatory bowel disease: a systematic review and meta-analysis.","volume":"11","author":"Karreman","year":"2017","journal-title":"J Crohns Colitis"},{"issue":"3","key":"jrv200013r17","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","article-title":"The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease.","volume":"10","author":"Harbord","year":"2016","journal-title":"J Crohns Colitis"},{"issue":"2","key":"jrv200013r18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3109\/07853890903559724","article-title":"Extraintestinal manifestations of inflammatory bowel disease: epidemiology, diagnosis, and management.","volume":"42","author":"Larsen","year":"2010","journal-title":"Ann Med"},{"issue":"1","key":"jrv200013r19","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/ajg.2010.343","article-title":"Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort.","volume":"106","author":"Vavricka","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"jrv200013r20","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1148\/radiol.10091953","article-title":"Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography.","volume":"256","author":"Dave","year":"2010","journal-title":"Radiology"},{"issue":"11","key":"jrv200013r21","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1038\/s41395-018-0204-7","article-title":"Legal risks and considerations associated with inflammatory bowel disease: a primer.","volume":"113","author":"Feld","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"jrv200013r22","article-title":"Aminosalicylates for induction of remission or response in Crohn's disease.","volume":"7","author":"Lim","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"jrv200013r23","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1056\/NEJM199502023320503","article-title":"Methotrexate for the treatment of Crohn\u2019s disease.","volume":"332","author":"Feagan","year":"1995","journal-title":"N Engl J Med"},{"issue":"22","key":"jrv200013r24","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJM200006013422202","article-title":"A comparison of methotrexate with placebo for the maintenance of remission in Crohn\u2019s disease.","volume":"342","author":"Feagan","year":"2000","journal-title":"N Engl J Med"},{"issue":"15","key":"jrv200013r25","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease.","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"issue":"10","key":"jrv200013r26","article-title":"Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease.","author":"Chande","year":"2015","journal-title":"Cochrane Database of Syst Rev"},{"issue":"4","key":"jrv200013r27","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1053\/j.gastro.2013.06.009","article-title":"Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn\u2019s disease.","volume":"145","author":"Pan\u00e9s","year":"2013","journal-title":"Gastroenterology"},{"issue":"4","key":"jrv200013r28","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1053\/j.gastro.2013.04.048","article-title":"Early administration of azathioprine vs conventional management of Crohn\u2019s Disease: a randomized controlled trial.","volume":"145","author":"Cosnes","year":"2013","journal-title":"Gastroenterology"},{"issue":"2","key":"jrv200013r29","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the CLASSIC-I trial.","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"issue":"1","key":"jrv200013r30","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial.","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"issue":"3","key":"jrv200013r31","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn\u2019s disease.","volume":"357","author":"Sandborn","year":"2007","journal-title":"N Engl J Med"},{"issue":"3","key":"jrv200013r32","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa062897","article-title":"Maintenance therapy with certolizumab pegol for Crohn\u2019s disease.","volume":"357","author":"Schreiber","year":"2007","journal-title":"N Engl J Med"},{"issue":"20","key":"jrv200013r33","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s Disease.","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"jrv200013r34","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease.","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"jrv200013r35","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG clinical guideline: management of Crohn\u2019s disease in adults.","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"10114","key":"jrv200013r36","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of tight control management on Crohn\u2019s disease (CALM): a multicentre, randomised, controlled phase 3 trial.","volume":"390","author":"Colombel","year":"2018","journal-title":"Lancet"},{"issue":"10006","key":"jrv200013r37","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/S0140-6736(15)00068-9","article-title":"Early combined immunosuppression for the management of Crohn\u2019s disease (REACT): a cluster randomised controlled trial.","volume":"386","author":"Khanna","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"jrv200013r38","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/ecco-jcc\/jjz131","article-title":"Outcomes and strategies to support a treat-to-target approach in inflammatory bowel disease: a systematic review.","volume":"14","author":"Colombel","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"5","key":"jrv200013r39","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/j.1365-2036.2011.04975.x","article-title":"Meta-analysis: diagnostic medical radiation exposure in inflammatory bowel disease.","volume":"35","author":"Chatu","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"jrv200013r41","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/s10620-011-1671-5","article-title":"Relapse rate following azathioprine withdrawal in maintaining remission for Crohn\u2019s disease: a meta-analysis.","volume":"56","author":"French","year":"2011","journal-title":"Dig Dis Sci"},{"issue":"5","key":"jrv200013r42","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/ajg.2016.54","article-title":"The risk of relapse after anti-TNF discontinuation in inflammatory bowel disease: systematic review and meta-analysis.","volume":"111","author":"Gisbert","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"jrv200013r43","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/ajg.2017.438","article-title":"Defining an optimal adherence threshold for patients taking subcutaneous anti-TNFs for inflammatory bowel diseases.","volume":"113","author":"Govani","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"jrv200013r44","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1053\/j.gastro.2016.10.013","article-title":"Drug safety and risk of adverse outcomes for pregnant patients with inflammatory bowel disease.","volume":"152","author":"Mahadevan","year":"2017","journal-title":"Gastroenterology"},{"issue":"6","key":"jrv200013r45","first-page":"1091","article-title":"Birth outcomes in women with inflammatory bowel disease: effects of disease activity and drug exposure.","volume":"20","author":"Br\u00f6ms","year":"2014","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"jrv200013r46","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1097\/MIB.0000000000000092","article-title":"Anti-TNFa therapies are safe during pregnancy in women with inflammatory bowel disease: a systematic review and meta-analysis.","volume":"20","author":"Narula","year":"2014","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"jrv200013r47","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1053\/j.gastro.2015.12.003","article-title":"The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy.","volume":"150","author":"Nguyen","year":"2016","journal-title":"Gastroenterology"},{"issue":"3","key":"jrv200013r48","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/ecco-jcc\/jju028","article-title":"Risk factors for postoperative intra-abdominal septic complications after surgery in Crohn\u2019s disease: a meta-analysis of observational studies.","volume":"9","author":"Huang","year":"2015","journal-title":"J Crohns Colitis"},{"issue":"5","key":"jrv200013r49","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1097\/MIB.0000000000000698","article-title":"Short bowel syndrome and intestinal failure in Crohn\u2019s disease.","volume":"22","author":"Limketkai","year":"2016","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"jrv200013r50","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1016\/j.cgh.2019.09.040","article-title":"Perioperative and postoperative management of patients with Crohn's disease and ulcerative colitis.","volume":"18","author":"Barnes","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"jrv200013r51","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1053\/j.gastro.2016.02.072","article-title":"Infliximab reduces endoscopic, but not clinical, recurrence of Crohn\u2019s disease after ileocolonic resection.","volume":"150","author":"Regueiro","year":"2016","journal-title":"Gastroenterology"},{"issue":"2","key":"jrv200013r52","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1053\/j.gastro.2003.11.010","article-title":"Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.","volume":"126","author":"Rutter","year":"2004","journal-title":"Gastroenterology"},{"issue":"12","key":"jrv200013r53","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1016\/j.cgh.2017.06.051","article-title":"Inflammatory bowel disease and small bowel cancer risk, clinical characteristics, and histopathology: a population-based study.","volume":"15","author":"Bojesen","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"jrv200013r54","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1111\/apt.2006.23.issue-8","article-title":"Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn\u2019s disease.","volume":"23","author":"Canavan","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"jrv200013r55","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.cgh.2013.04.033","article-title":"Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis.","volume":"12","author":"Singh","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"jrv200013r56","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1053\/j.gastro.2012.05.004","article-title":"Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease.","volume":"143","author":"Long","year":"2012","journal-title":"Gastroenterology"},{"issue":"17","key":"jrv200013r57","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease.","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"jrv200013r58","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cgh.2010.09.016","article-title":"A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease.","volume":"9","author":"Kotlyar","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"jrv200013r59","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.cgh.2012.06.016","article-title":"Effects of cancer treatment on inflammatory bowel disease remission and reactivation.","volume":"10","author":"Axelrad","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"jrv200013r60","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/j.gastro.2016.03.037","article-title":"Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: a systematic review and meta-analysis.","volume":"151","author":"Shelton","year":"2016","journal-title":"Gastroenterology"},{"issue":"10","key":"jrv200013r61","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1002\/art.39738","article-title":"Association between breast cancer recurrence and immunosuppression in rheumatoid arthritis and inflammatory bowel disease: a cohort study.","volume":"68","author":"Mamtani","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"jrv200013r62","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S2468-1253(19)30362-0","article-title":"Anti-tumour necrosis factor-a therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study.","volume":"5","author":"Waljee","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"jrv200013r63","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/ajg.2012.406","article-title":"Increased risk of pneumonia among patients with inflammatory bowel disease.","volume":"108","author":"Long","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"jrv200013r64","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1097\/MIB.0b013e3182802a9b","article-title":"Increased risk of pneumocystis jiroveci pneumonia among patients with inflammatory bowel disease.","volume":"19","author":"Long","year":"2013","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"jrv200013r65","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.cgh.2017.12.052","article-title":"Overall and comparative risk of herpes zoster with pharmacotherapy for inflammatory bowel diseases: a nationwide cohort study.","volume":"16","author":"Khan","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"jrv200013r66","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.cgh.2016.10.024","article-title":"Management of Clostridium difficile infection in inflammatory bowel disease: expert review from the Clinical Practice Updates Committee of the AGA Institute.","volume":"15","author":"Khanna","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"jrv200013r67","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/ajg.2016.537","article-title":"ACG clinical guideline: preventive care in inflammatory bowel disease.","volume":"112","author":"Farraye","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"jrv200013r68","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.gie.2014.10.030","article-title":"The role of endoscopy in inflammatory bowel disease.","volume":"81","author":"Shergill","year":"2015","journal-title":"Gastrointest Endosc"},{"issue":"8","key":"jrv200013r69","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.crohns.2014.02.002","article-title":"Smoking in inflammatory bowel disease: impact on disease course and insights into the aetiology of its effect.","volume":"8","author":"Parkes","year":"2014","journal-title":"J Crohns Colitis"},{"issue":"31","key":"jrv200013r70","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.3748\/wjg.v17.i31.3567","article-title":"Management of Crohn\u2019s disease in smokers: is an alternative approach necessary?","volume":"17","author":"Nos","year":"2011","journal-title":"World J Gastroenterol"},{"issue":"11","key":"jrv200013r71","first-page":"1064","article-title":"An assessment of the AGA and CCFA quality indicators in a sample of patients diagnosed with inflammatory bowel disease.","volume":"21","author":"Tkacz","year":"2015","journal-title":"J Manag Care Spec Pharm"},{"issue":"5","key":"jrv200013r72","first-page":"286","article-title":"Quality improvement in inflammatory bowel disease.","volume":"9","author":"Melmed","year":"2013","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"5","key":"jrv200013r73","first-page":"280","article-title":"Irritable bowel syndrome, disordered eating, and eating disorders.","volume":"15","author":"Harer","year":"2019","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"4","key":"jrv200013r74","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.cppeds.2017.02.005","article-title":"Avoidant\/restrictive food intake disorder (ARFID).","volume":"47","author":"Zimmerman","year":"2017","journal-title":"Curr Probl Pediatr Adolesc Health Care"},{"issue":"18","key":"jrv200013r75","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.3748\/wjg.v23.i18.3356","article-title":"Low-FODMAP diet reduces irritable bowel symptoms in patients with inflammatory bowel disease.","volume":"23","author":"Pedersen","year":"2017","journal-title":"World J Gastroenterol"},{"issue":"1","key":"jrv200013r76","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1053\/j.gastro.2019.09.024","article-title":"Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial.","volume":"158","author":"Cox","year":"2020","journal-title":"Gastroenterology"},{"key":"jrv200013r77","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jpsychores.2016.06.001","article-title":"Depression and anxiety in patients with inflammatory bowel disease: a systematic review.","volume":"87","author":"Neuendorf","year":"2016","journal-title":"J Psychosom Res"},{"issue":"4","key":"jrv200013r78","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s12664-018-0870-9","article-title":"Psychiatric comorbidities in patients with inflammatory bowel disease.","volume":"37","author":"Bhamre","year":"2018","journal-title":"Indian J Gastroenterol"},{"issue":"3","key":"jrv200013r79","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1097\/MIB.0000000000000620","article-title":"Controversies revisited: a systematic review of the comorbidity of depression and anxiety with inflammatory bowel diseases.","volume":"22","author":"Mikocka-Walus","year":"2016","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"jrv200013r80","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1016\/j.crohns.2012.09.010","article-title":"Inflammatory bowel disease and pregnancy: lack of knowledge is associated with negative views.","volume":"7","author":"Selinger","year":"2013","journal-title":"J Crohns Colitis"},{"issue":"5","key":"jrv200013r81","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/ibd.20082","article-title":"Voluntary childlessness is increased in women with inflammatory bowel disease.","volume":"13","author":"Marri","year":"2007","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"jrv200013r82","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/ibd.20839","article-title":"Fear and fertility in inflammatory bowel disease: a mismatch of perception and reality affects family planning decisions.","volume":"15","author":"Mountifield","year":"2009","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"jrv200013r83","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1093\/ibd\/izz032","article-title":"Initial assessment of post-traumatic stress in a US cohort of inflammatory bowel disease patients.","volume":"25","author":"Taft","year":"2019","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"jrv200013r84","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1037\/ccp0000227","article-title":"Effectiveness of cognitive-behavioral therapy on quality of life, anxiety, and depressive symptoms among patients with inflammatory bowel disease: a multicenter randomized controlled trial.","volume":"85","author":"Bennebroek Evertsz\u2019","year":"2017","journal-title":"J Consult Clin Psychol"},{"issue":"5","key":"jrv200013r85","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1093\/ibd\/izy367","article-title":"The influence of antidepressants on the disease course among patients with Crohn\u2019s disease and ulcerative colitis-a danish nationwide register-based cohort study.","volume":"25","author":"Kristensen","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"jrv200013r40","volume-title":"Health Risks From Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2","author":"Council","year":"2006"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2774686\/jama_cushing_2021_rv_200013_1609784449.58034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T07:41:51Z","timestamp":1610091711000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2774686"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2021,1,5]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,5]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2020.18936","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,5]]}}}